As of March 23, 2026, Cumberland Pharmaceuticals's top three insider holders are A J Kazimi (Chairman And Ceo, 5.70Mn shares), Kenneth Krogulski (Director, 296.54K shares), Martin E Cearnal (Sr Vp/Chief Commercial Officer, 163.47K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| A J Kazimi | Chairman And Ceo | 5,695,310 | 0 | 18 Mar, 2026 |
| Kenneth Krogulski | 302,338 | 0 | 20 Mar, 2026 | |
| Martin E Cearnal | Sr Vp/Chief Commercial Officer | 163,473 | 0 | 29 Apr, 2022 |
| Leo Pavliv | Svp And Chief Development Off. | 129,618 | 0 | 01 Jul, 2022 |
| Joey A Jacobs | 98,415 | 0 | 21 Mar, 2023 | |
| Joseph C Galante | 63,656 | 0 | 20 Mar, 2026 | |
| James Jones | 46,863 | 0 | 20 Mar, 2026 | |
| James L Herman | Vp And Chief Compliance Office | 38,255 | 0 | 26 Mar, 2024 |
| Caroline Young | 35,109 | 0 | 20 Mar, 2026 | |
| John M. Hamm | Vp Chief Financial Officer | 20,073 | 0 | 18 Mar, 2025 |
| Todd M. Anthony | Vice Pres Organizational Dev | 16,328 | 0 | 26 Mar, 2024 |
| Martin S Jr Brown | 10,300 | 0 | 20 Mar, 2026 | |
| Chris T. Bitterman | Vice Pres Sales Marketing | 4,683 | 0 | 26 Mar, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 18 Mar, 2026 | Chris T. Bitterman | Options (right to buy) | A | 3,000 | $2.80 | 19,000 | D | A |
| 18 Mar, 2026 | A J Kazimi | Options (right to buy) | A | 100,000 | $2.80 | 568,000 | D | A |
| 18 Mar, 2026 | Joseph C Galante | Common Stock | A | 1,800 | $2.80 | 63,656 | D | A |
| 18 Mar, 2026 | James Jones | Common Stock | A | 1,800 | $2.80 | 46,863 | D | A |
| 18 Mar, 2026 | Kenneth Krogulski | Common Stock | A | 1,800 | $2.80 | 298,338 | D | A |
| 18 Mar, 2026 | Todd M. Anthony | Options (right to buy) | A | 3,000 | $2.80 | 21,000 | D | A |
| 18 Mar, 2026 | Martin S Jr Brown | Common Stock | A | 1,800 | $2.80 | 10,300 | D | A |
| 18 Mar, 2026 | Caroline Young | Common Stock | A | 1,800 | $2.80 | 35,109 | D | A |
| 18 Mar, 2026 | James L Herman | Options (right to buy) | A | 2,500 | $2.80 | 21,000 | D | A |
| 18 Mar, 2026 | John M. Hamm | Options (right to buy) | A | 3,000 | $2.80 | 18,250 | D | A |
| 18 Mar, 2026 | Kenneth Krogulski | Common Stock | A | 4,000 | $2.80 | 302,338 | D | A |
| 16 Mar, 2026 | A J Kazimi | Common Stock | D | 5,845 | $3.06 | 5,695,310 | D | F |
| 01 Dec, 2025 | Kenneth Krogulski | Common Stock | A | 124 | $2.36 | 294,746 | D | L |
| 01 Dec, 2025 | James Jones | Common Stock | A | 18 | $2.36 | 44,811 | D | L |
| 01 Dec, 2025 | Caroline Young | Common Stock | A | 4 | $2.36 | 33,247 | D | L |
| 01 Dec, 2025 | A J Kazimi | Common Stock | A | 18 | $2.36 | 5,700,903 | D | L |
| 02 Dec, 2025 | Kenneth Krogulski | Common Stock | A | 124 | $2.24 | 294,870 | D | L |
| 02 Dec, 2025 | Caroline Young | Common Stock | A | 4 | $2.24 | 33,251 | D | L |
| 02 Dec, 2025 | James Jones | Common Stock | A | 18 | $2.24 | 44,829 | D | L |
| 02 Dec, 2025 | A J Kazimi | Common Stock | A | 18 | $2.24 | 5,700,921 | D | L |